Trial Profile
A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Study on the Use of Rho-Kinase Inhibitor to Reduce Ore Prevent Proliferative Vitreoretinopathy (PVR) in Eyes With Rhegmatogenous Retinal Detachment (RRD) at High Risk of PVR
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Netarsudil (Primary) ; Glycerol; Hypromellose; Polyethylene glycol
- Indications Proliferative vitreoretinopathy; Retinal detachment
- Focus Therapeutic Use
- 24 Apr 2023 Status changed from not yet recruiting to recruiting.
- 22 Dec 2022 New trial record